Biomedical Engineering Reference
In-Depth Information
44. Smith KT, Shepherd AJ, Boyd JE et al. Gene delivery systems for use in gene therapy: An over-
view of quality assurance and safety issues. Gene Ther 1996; 3(3):190-200.
45. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy.
Hum Gene Ther 1994; 5(7):793-801.
46. Kessler PD, Podsakoff GM, Chen X et al. Gene delivery to skeletal muscle results in sustained
expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996;
93(24):14082-7.
47. Wu P, Phillips MI, Bui J et al. Adeno-associated virus vector-mediated transgene integration into
neurons and other nondividing cell targets. J Virol 1998; 72(7):5919-26.
48. Snyder RO, Spratt SK, Lagarde C et al. Efficient and stable adeno-associated virus-mediated trans-
duction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997;
8(16):1891-900.
49. Moskalenko M, Chen L, van Roey M et al. Epitope mapping of human anti-adeno-associated virus
type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J Virol 2000;
74(4):1761-6.
50. Chirmule N, Propert K, Magosin S et al. Immune responses to adenovirus and adeno-associated
virus in humans. Gene Ther 1999; 6(9):1574-83.
51. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-
associated viruses. J Natl Cancer Inst 1968; 40(2):319-27.
52. Chirmule N, Xiao W, Truneh A et al. Humoral immunity to adeno-associated virus type 2 vectors
following administration to murine and nonhuman primate muscle. J Virol 2000; 74(5):2420-5.
53. Fisher KJ, Jooss K, Alston J et al. Recombinant adeno-associated virus for muscle directed gene
therapy. Nat Med 1997; 3(3):306-12.
54. Xiao W, Chirmule N, Schnell MA et al. Route of administration determines induction of
T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1(4):323-9.
55. Xiao W, Chirmule N, Berta SC et al. Gene therapy vectors based on adeno-associated virus type 1.
J Virol 1999; 73(5):3994-4003.
56. Gao G, Qu G, Burnham MS et al. Purification of recombinant adeno-associated virus vectors by
column chromatography and its performance in vivo. Hum Gene Ther 2000; 11(15):2079-91.
57. Nicklin SA, Buening H, Dishart KL et al. Efficient and selective AAV2-mediated gene transfer
directed to human vascular endothelial cells. Mol Ther 2001; 4(3):174-81.
58. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for
adeno-associated virus type 2 virions. J Virol 1998; 72(2):1438-45.
59. Qing K, Mah C, Hansen J et al. Human fibroblast growth factor receptor 1 is a coreceptor for
infection by adeno-associated virus 2. Nat Med 1999; 5(1):71-7.
60. Zolotukhin S, Byrne BJ, Mason E et al. Recombinant adeno-associated virus purification using
novel methods improves infectious titer and yield. Gene Ther 1999; 6(6):973-85.
61. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production
of recombinant virus. Virology 1999; 265(2):274-85.
62. Wu P, Xiao W, Conlon T et al. Mutational analysis of the adeno-associated virus type 2 (AAV2)
capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74(18):8635-47.
63. Girod A, Ried M, Wobus C et al. Genetic capsid modifications allow efficient retargeting of
adeno-associated virus type 2. Nat Med 1999; 5(12):1438.
64. Kaplitt MG, Leone P, Samulski RJ et al. Long-term gene expression and phenotypic correction
using adeno- associated virus vectors in the mammalian brain. Nat Genet 1994; 8(2):148-54.
65. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompe-
tent mice by adeno-associated virus vector. J Virol 1996; 70(11):8098-108.
66. Snyder RO, Miao CH, Patijn GA et al. Persistent and therapeutic concentrations of human factor
IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16(3):270-6.
67. Flotte T, Carter B, Conrad C et al. A phase I study of an adeno-associated virus-CFTR gene
vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7(9):1145-59.
68. Wagner JA, Reynolds T, Moran ML et al. Efficient and persistent gene transfer of AAV-CFTR in
maxillary sinus. Lancet 1998; 351(9117):1702-3.
69. Ponnazhagan S, Erikson D, Kearns WG et al. Lack of site-specific integration of the recombinant
adeno-associated virus 2 genomes in human cells. Hum Gene Ther 1997; 8(3):275-84.
70. Kay MA, Manno CS, Ragni MV et al. Evidence for gene transfer and expression of factor IX in
haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24(3):257-61.
71. Pan RY, Xiao X, Chen SL et al. Disease-inducible transgene expression from a recombinant
adeno-associated virus vector in a rat arthritis model. J Virol 1999; 73(4):3410-7.
72. Goater J, Muller R, Kollias G et al. Empirical advantages of adeno associated viral vectors in vivo
gene therapy for arthritis. J Rheumatol 2000; 27(4):983-9.
Search WWH ::
Custom Search